Wilson's T3 Plateau: When the Protocol Stops Working and Research-Community Responses

The Wilson's WT3 protocol is the most structured cyclic T3 approach in the bioenergetic research community. Its design is rigorous: begin slow-release T3 at a conservative dose, titrate upward in measured increments every several days, hold at the dose that sustains an oral average temperature of 98.6 degrees Fahrenheit for a minimum of three consecutive weeks, then taper to allow the endogenous thyroid axis to resume at a corrected set point. For many research subjects, the protocol delivers the outcome it promises.

For a recognizable subset, it does not. The research subject titrates upward through the standard dose ladder. Temperature rises encouraging, then stalls. Additional dose increases produce diminishing returns. In some cases the temperature reaches 98.6 degrees Fahrenheit briefly, then falls back - not to baseline, but to 97.8 or 97.4, where it holds regardless of further titration. In other presentations the subject never reaches target temperature at all, plateauing at 97.5 or 98.0 despite doses that should, by protocol logic, be sufficient. In a third variation, temperature reaches and holds at target but symptoms - fatigue, cognitive difficulty, cold intolerance, body composition stagnation - persist as if the temperature signal is disconnected from the metabolic outcomes it is supposed to drive.

This pattern - the Wilson's T3 plateau - is a consistently reported phenomenon in the bioenergetic research community. Its causes are mechanistically distinct, its management differs depending on which cause is driving it, and the research-community response to the most common conversion-bottleneck presentation has evolved in a specific direction that the original WT3 protocol did not anticipate.

Research framing. This article reviews Wilson's WT3 protocol plateau patterns from a research-context standpoint. All compounds discussed are sold strictly for laboratory research and not for human consumption. See our FAQ on research legality for full terms.

The Plateau Patterns: Three Distinct Presentations

Not all Wilson's T3 plateaus are the same. The research-community literature describes three distinct presentations that each carry different mechanism profiles and call for different investigative responses.

Pattern A: Reach target, then regress. The research subject successfully titrates to a dose that brings average temperature to 98.6 degrees Fahrenheit. The target is held for several days - sometimes a week or more - and then temperature begins to fall back despite continuing the same dose. A dose increase may produce a brief secondary rise, but regression follows again. This pattern is typically associated with either reverse T3 re-accumulation (DIO3 compensatory upregulation re-saturating thyroid receptors) or a loss of the initial T3 sensitization effect as the body adapts.

Pattern B: Never reach target despite full titration. The research subject follows the standard titration ladder through doses that exceed the typical effective range. Temperature rises with initial dose increases but progress flattens well below 98.6 degrees Fahrenheit. Further increases produce little temperature response. Heart rate may increase, indicating systemic T3 activity, but temperature remains stuck. This pattern often points to a conversion-bottleneck mechanism - adequate T3 signal is present at the receptor level, but the downstream metabolic activation that should raise temperature is incomplete. The T3-to-T2 conversion step is the most mechanistically coherent explanation for this presentation.

Pattern C: Temperature reached, symptoms persist. This is the presentation that confounds conventional explanation most directly. Average temperature reaches and holds at 98.6 degrees Fahrenheit. The protocol's primary objective metric is satisfied. Yet the research subject continues to report persistent fatigue, cognitive difficulty, cold intolerance at the extremities, and body composition that does not respond. Free T3 measured in serum may be at the upper end of the reference range. TSH is appropriately suppressed. By standard panel metrics, the protocol is working. Yet the subject does not feel or function as if their metabolism has normalized. This pattern is the clearest signal of a downstream conversion problem - specifically the T3-to-T2 bottleneck that leaves mitochondrial function undersupported even when nuclear thyroid receptor signaling appears adequate.

Each pattern overlaps with the others, and more than one mechanism may be operating simultaneously in the same research subject. The investigative value of distinguishing between them lies in directing the response: addressing the driving mechanism rather than simply escalating T3 dose.

The T3 to T2 Conversion Bottleneck Explanation

The most discussed bioenergetic-research explanation for the Wilson's T3 plateau - particularly Pattern B and Pattern C - is the second-step conversion bottleneck. Understanding why requires a brief re-examination of what the WT3 protocol actually provides and what it does not.

The Wilson's protocol provides T3 directly. This bypasses the impaired T4-to-T3 step that characterizes the underlying Wilson's Temperature Syndrome presentation - the step at which type 1 deiodinase (DIO1) and type 2 deiodinase (DIO2) are supposed to convert the prohormone T4 into active T3, but fail to do so adequately due to selenium deficiency, systemic inflammation, elevated cortisol, or low ferritin. By supplying T3 exogenously, the WT3 protocol ensures that nuclear thyroid receptors receive adequate T3 signal regardless of how impaired the T4-to-T3 conversion machinery is.

What the protocol does not provide - and what the original Wilson's framework did not fully account for - is 3,5-T2 (3,5-diiodothyronine). T3 is not the terminal product of thyroid hormone metabolism. Once T3 is present in peripheral tissues, DIO1 acts on it to produce downstream diiodothyronine products. The metabolically significant isomer is 3,5-T2, which acts through a fundamentally different mechanism than T3: rather than binding nuclear thyroid receptors and initiating genomic transcription cascades, 3,5-T2 binds directly to subunit Va of cytochrome c oxidase - Complex IV of the mitochondrial electron transport chain - and acutely elevates aerobic respiration on a timescale of minutes rather than hours. This is the mechanism established by Goglia and colleagues in the landmark 1994 FEBS Letters paper, which has been cited in subsequent T2 research for three decades.

The critical point for the plateau discussion is this: T3 cannot replicate the cytochrome c oxidase pathway regardless of how much of it is present. Nuclear thyroid receptor signaling and mitochondrial cytochrome c oxidase activation are distinct mechanisms driven by distinct molecules. A research subject receiving exogenous T3 has addressed the first pathway. Whether the second pathway is adequately supported depends entirely on whether DIO1 is successfully converting that T3 into 3,5-T2 at the peripheral tissue level.

This is where the bottleneck becomes structurally predictable. The conditions that create the original need for a T3 protocol - selenium deficiency, systemic inflammation, cortisol excess, deiodinase imbalance - are the same conditions that impair DIO1's ability to perform the T3-to-T2 conversion step. DIO1 is a selenoprotein: it requires selenium in the form of selenocysteine at its active site for catalytic function. Selenium deficiency degrades DIO1 activity across all of its conversion responsibilities simultaneously. The same inflammatory cytokines (IL-6, TNF-alpha, IL-1beta) that suppress T4-to-T3 conversion also suppress T3-to-T2 conversion through the same DIO1 inhibition pathway. A research subject who needed the WT3 protocol because their deiodinase function was impaired is also, by that same mechanism, impaired at the T3-to-T2 step. Providing more T3 does not solve an enzyme-capacity problem.

This explains the characteristic presentation of the conversion-bottleneck plateau. Standard serum free T3 may be in the upper third of the reference range - the T3 is present. TSH is suppressed - the nuclear thyroid receptor signal is reaching the HPT axis. Reverse T3 may be normalized - the rT3 dominance pattern has been cleared. Yet the research subject's temperature will not reach 98.6 degrees Fahrenheit, or if it does, the broader metabolic normalization does not follow. Body temperature in the context of thyroid hormone function reflects mitochondrial thermogenesis as much as nuclear receptor signaling - and mitochondrial thermogenesis depends specifically on the cytochrome c oxidase activation pathway that only 3,5-T2 drives.

For a detailed review of the DIO1 mechanism, the T3-to-T2 conversion pathway, and the evidence base for 3,5-T2's distinct mitochondrial mechanism, see the T3-to-T2 conversion problem and deiodinase dysfunction guide. It is the centerpiece reference for understanding why adding T2 directly is the mechanistically coherent response to this specific plateau pattern - and why increasing T3 dose will not resolve it when conversion capacity is the limiting factor. The Wilson's T3+T2 Combo is the reference product for researchers investigating the combined approach that bypasses this bottleneck directly.

The Reverse T3 Re-Accumulation Pattern

The second most commonly discussed Wilson's T3 plateau explanation is reverse T3 re-accumulation, which is the primary mechanism the original WT3 protocol framework anticipated.

The WT3 protocol addresses the rT3-dominant state by overwhelming it with exogenous T3: as T3 rises through titration, TSH suppresses and T4 production falls, which starves out the DIO3-driven rT3 generation that was sustained by high T4 availability. Reverse T3 clears as T4 substrate falls and as sufficient T3 competes at receptor sites. This mechanism is why the protocol requires sustained T3 delivery over weeks rather than days - the rT3 clearance process is gradual, and temperature stabilization at 98.6 degrees Fahrenheit for three consecutive weeks is the established endpoint for confirming that the rT3 saturation has been cleared.

The re-accumulation pattern occurs when the initial titration successfully clears rT3 enough to bring temperature toward target - but then, during the sustained high-T3 phase, DIO3 activity compensates. DIO3 is the deiodinase responsible for converting T3 into rT3 (rather than T4 being converted to rT3 by DIO3 acting on T4 - DIO3 also acts on T3 directly, producing rT3 as a T3 catabolic product). As exogenous T3 rises to high levels over multiple weeks, DIO3 upregulates as a protective response, beginning to process that T3 into rT3 rather than allowing it to remain as active T3 at receptor sites. The result is a progressive re-saturation of the rT3 pool that counteracts the initial clearance.

This explains Pattern A - the subject who reaches target temperature and then falls back. The initial rT3 clearance is genuine; the regression represents DIO3 re-establishing a compensatory rT3 load in response to the sustained elevated T3 input. Pushing the T3 dose higher at this point is generally counterproductive: it provides more substrate for DIO3-mediated rT3 production rather than extending the clearance. The standard WT3 response to this pattern is the planned taper - initiating the taper phase on schedule rather than fighting the re-accumulation with escalating T3, then addressing the upstream rT3 drivers during the between-cycle interval.

The upstream drivers of DIO3 overactivity are the same factors that drove the original rT3 dominance: chronic stress, systemic inflammation, caloric restriction, and infections. Addressing these during the taper and inter-cycle period creates a more favorable environment for a successful reset on the next cycle. For a comprehensive review of reverse T3 mechanisms, FT3:rT3 ratio interpretation, and the full range of rT3 drivers, see the reverse T3 complete guide.

Selenium and Iron Confounders

The cofactor status of a research subject entering the Wilson's WT3 protocol is one of the most commonly overlooked variables in plateau presentations, and it operates at a foundational biochemical level.

DIO1 is a selenoprotein. Like DIO2 and DIO3, it requires selenium incorporated as selenocysteine at its catalytic active site for functional activity. This is not a marginal cofactor requirement - selenium is structural to the enzyme. When selenium is deficient, DIO1 synthesis continues but the enzyme cannot achieve its full catalytic conformation. The result is reduced deiodinase activity across all conversion steps that DIO1 mediates: the T4-to-T3 step, the T3-to-T2 step, and the reverse T3 processing step. Selenium deficiency is therefore a single-point failure that simultaneously impairs multiple thyroid hormone conversion steps.

The research literature on selenium and deiodinase function establishes this relationship clearly. DIO1, DIO2, and DIO3 are all selenoproteins; selenium repletion in deficient subjects consistently improves deiodinase activity markers. In the Wilson's WT3 plateau context, this means a research subject with selenium deficiency is running the protocol with impaired conversion capacity at the fundamental enzyme level - more T3 input will not compensate for the enzyme that cannot process it. The practical threshold that has been discussed in research-community forums as the minimum for adequate deiodinase support is selenium in the mid-to-upper reference range, which typically requires active repletion in subjects on restricted diets or with gastrointestinal absorption issues. See the selenium and thyroid T3 conversion guide for a complete review of this relationship.

Iron is a separate but comparably important confounder. The hepatic T4-to-T3 conversion process, which is one of the primary peripheral conversion sites, depends on iron availability for a key step in its metabolic pathway. Ferritin below approximately 70 ng/mL is consistently associated with impaired thyroid hormone conversion in multiple case series and observational studies. This threshold - 70 ng/mL - is substantially higher than the conventional laboratory lower reference limit for ferritin, which may be as low as 12 to 15 ng/mL for women. A research subject whose ferritin is reported as "normal" at 25 ng/mL is operating with a meaningful iron-related conversion deficit by the research-community threshold.

The practical implication for plateau management is direct: confirming selenium status and ferritin status before escalating T3 dose is standard investigative practice in the research community. If ferritin is below 70 ng/mL, iron repletion before further T3 titration is the recommended sequence - not because higher T3 cannot be tolerated, but because the conversion deficit driven by low ferritin will limit the response to any T3 dose increase until the cofactor is restored. Similarly, selenium optimization before T2 supplementation ensures that whatever endogenous conversion capacity remains is operating at its best possible rate.

The Cortisol Confounder

Cortisol excess occupies a distinctive position in the Wilson's T3 plateau mechanism - it operates through multiple distinct pathways simultaneously, each of which can contribute to plateau independently.

The direct deiodinase pathway is the best-characterized: elevated cortisol suppresses DIO1 activity and upregulates DIO3 activity, shifting the deiodinase balance away from active T3 production and toward rT3 production. This is the mechanism by which the original Wilson's Temperature Syndrome often develops in the first place - a significant stressor drives cortisol elevation, which shifts the deiodinase balance toward the low-temperature, high-rT3 state that persists even after the stressor resolves. During a Wilson's WT3 protocol cycle, a concurrent period of elevated cortisol - from chronic workplace stress, acute infection, sleep deprivation, or financial or relationship crisis - can reactivate the same DIO3-dominance pattern that the protocol is attempting to clear. The protocol is running against the current.

The pregnenolone steal pathway adds another layer. Pregnenolone is the master steroid precursor from which cortisol, DHEA, progesterone, testosterone, and other protective steroids are synthesized. Under conditions of chronic stress, the steroidogenic pathway preferentially directs pregnenolone toward cortisol production, reducing the availability of downstream protective steroids - DHEA, progesterone, and testosterone - that modulate DIO1 activity and thyroid receptor sensitivity. The net effect is a hormonal environment in which cortisol is elevated and the protective steroids that buffer thyroid hormone function are depleted, creating a compounded impairment to the Wilson's protocol response.

A third mechanism operates at the receptor level. High cortisol can reduce the sensitivity of thyroid hormone receptors to T3, requiring higher effective T3 concentrations to achieve the same nuclear receptor activation. This raises the effective dose threshold for temperature normalization without changing the actual serum T3 level.

Wilson's WT3 plateau during a high-stress life period is a pattern the research community recognizes clearly. The subject reports that the protocol worked well during a calmer period, then stopped working when a significant stressor arose - or that they have been unable to break through a plateau that started coincidentally with a period of elevated life stress. The investigative response involves assessing morning cortisol, addressing adrenal cofactors, and for severe presentations, evaluating whether adrenal support is needed before the T3 titration can progress. For a complete review of the T3-cortisol-adrenal relationship, see the T3, adrenal fatigue, and cortisol connection guide.

The T3+T2 Enhanced-Protocol Response

When the Wilson's T3 plateau presents as the conversion-bottleneck pattern - adequate serum T3, suppressed TSH, normalized or acceptable rT3, yet temperature and symptoms not normalizing as expected - the response that the bioenergetic research community has moved toward is the Wilson's T3+T2 Enhanced Protocol.

The logic is direct. If the limiting step is DIO1's conversion of T3 to 3,5-T2, then providing more T3 does not solve the problem: it increases T3 accumulation without proportionally increasing T2 output, because the conversion enzyme is the constraint, not the substrate. The solution is to bypass the conversion step entirely by supplying T2 directly alongside T3.

In the enhanced protocol, each T3 dose step in the standard Wilson's titration ladder is paired with a matched T2 dose at a 1:1 mcg ratio. Where the standard WT3 protocol might titrate through 7.5 mcg, 15 mcg, and 22.5 mcg of SR-T3 twice daily, the enhanced protocol pairs each of those steps with an equivalent T2 dose: 7.5 mcg T3 + 7.5 mcg T2 twice daily, then 15 mcg T3 + 15 mcg T2 twice daily, and so on. The 1:1 ratio is not intended to replicate precise physiological T3:T2 ratios, which are highly individual and variable - it ensures that both the nuclear receptor pathway (served by T3) and the mitochondrial cytochrome c oxidase pathway (served by 3,5-T2) receive direct supplementation at proportional doses, regardless of whether endogenous conversion is functional.

The T2 component bypasses the DIO1 bottleneck entirely. Once 3,5-T2 is supplied directly, it does not depend on DIO1 to reach cytochrome c oxidase subunit Va. It reaches that binding site directly, driving acute mitochondrial respiration elevation on the timescale of hours rather than the days-to-weeks timescale of the nuclear receptor transcription cascade. The thermogenic and metabolic effects that the temperature target is meant to capture - mitochondrial heat production, fatty acid oxidation, cellular energy efficiency - become accessible through the T2 route independently of whether T3-to-T2 conversion is intact.

The practical implication is that research subjects who plateau on the standard Wilson's WT3 protocol at doses where rT3 is controlled and free T3 is adequate are candidates for the T2 addition rather than further T3 escalation. Escalating T3 beyond what is needed to clear rT3 and saturate nuclear receptors carries incremental HPT-axis suppression cost without addressing the mitochondrial deficit if conversion is impaired. Adding T2 directly addresses the mitochondrial deficit at its actual location in the mechanism, without requiring T3 to perform a conversion step it cannot adequately complete.

For the full titration structure, timing, monitoring framework, and how the T2 component integrates with the cyclic Wilson's approach, see the Wilson's T3+T2 Enhanced Protocol guide. The Wilson's T3+T2 Combo is the reference product formulated at the 1:1 sustained-release ratio for this research application. For researchers already established on a slow-release T3 base who want to investigate the full conversion-supporting combination including T2, the Wilson's SR-T3 Combo is also relevant context in the SR-T3 product framework.

Response Framework: Working Through the Plateau

What Research Has and Hasn't Established

Established:

DIO1 produces 3,3'-T2 from T3 as its primary catabolic route - this is established deiodinase biochemistry documented in the peer-reviewed literature. Selenium is a required cofactor for all three deiodinases (DIO1, DIO2, DIO3); selenium deficiency impairs deiodinase activity across the family - this is well-replicated in animal models and clinical observations. Systemic inflammation, specifically via cytokine-mediated suppression, degrades DIO activity broadly - also well-documented. 3,5-T2 binds cytochrome c oxidase subunit Va and directly elevates mitochondrial respiration - established by the 1994 Goglia et al. paper and supported by subsequent replication. The Wilson's WT3 cyclic T3 protocol is documented in the bioenergetic-research community literature as a structured approach to reverse T3 dominance and low body temperature.

Hypothesis:

The conversion-bottleneck explanation for WT3 plateau - the specific hypothesis that adequate serum T3 with persistent metabolic underperformance reflects impaired T3-to-T2 conversion rather than (or in addition to) residual rT3 dominance - is mechanistically coherent but has not been validated as the dominant explanation in head-to-head trials. The same applies to the T3+T2 enhanced protocol as the specific response: it is research-community theory built on real and individually documented mechanisms, not on randomized controlled-trial evidence for the combination as a plateau-resolution strategy. The mechanistic reasoning is solid; the clinical validation is not yet present.

Not endorsed by mainstream endocrinology:

The Wilson's WT3 protocol AND its T3+T2 enhanced extension operate entirely outside mainstream clinical guidelines. Mainstream endocrinology does not recognize Wilson's Temperature Syndrome as a formal clinical diagnosis, does not endorse cyclic T3 protocols as a treatment approach for most thyroid presentations, and does not include T2 supplementation in any clinical guideline. Researchers engaging with this framework should be aware they are working with mechanistically-grounded but clinically unvalidated models, and should apply appropriate experimental rigor, monitoring, and caution.

Frequently Asked Questions

What is Wilson's T3 plateau?

Wilson's T3 plateau refers to a stall in the expected response to the Wilson's WT3 protocol - the cyclic slow-release T3 approach designed to clear reverse T3 dominance and restore normal body temperature. The plateau presents as either a failure to reach the target temperature of 98.6 degrees Fahrenheit despite full titration, an initial reach of target temperature followed by regression, or target temperature achieved but with symptoms persisting as if the metabolic normalization is incomplete. The Wilson's T3 plateau is a consistently reported pattern in the bioenergetic research community.

Why does Wilson's T3 protocol stop working?

The Wilson's T3 protocol may plateau for several distinct reasons depending on the case: reverse T3 re-accumulation (DIO3 compensating against the sustained high-T3 input), the T3-to-T2 conversion bottleneck (DIO1 impairment preventing downstream 3,5-T2 production needed for mitochondrial activation), selenium or iron cofactor deficiency limiting deiodinase function, or cortisol elevation impairing DIO1 directly and upregulating DIO3. In practice more than one of these mechanisms may be operating simultaneously in the same research subject.

What is the T3 to T2 conversion bottleneck?

The T3-to-T2 conversion bottleneck is a research-community hypothesis that explains a specific Wilson's plateau pattern: adequate serum free T3, suppressed TSH, acceptable rT3, but temperature and metabolic markers that will not normalize. The hypothesis holds that DIO1 - the same deiodinase enzyme impaired by selenium deficiency and inflammation in the original T4-to-T3 bottleneck - is also impaired at the downstream T3-to-3,5-T2 conversion step. Because 3,5-T2 drives mitochondrial activation via cytochrome c oxidase (a mechanism T3 cannot replicate), impaired T3-to-T2 conversion leaves mitochondrial function undersupported even when nuclear thyroid receptor signaling is adequate. For a detailed review, see the T3-to-T2 conversion problem guide.

Should I increase my T3 dose if I plateau on Wilson's protocol?

Not automatically. The appropriate response depends on which plateau pattern is present. If reverse T3 is rising, increasing T3 dose may worsen rT3 production; the standard response is to initiate the planned taper rather than escalate. If the plateau reflects a conversion bottleneck - adequate free T3 with persistent metabolic underperformance - escalating T3 adds substrate that DIO1 cannot adequately process, rather than solving the conversion problem. If cofactors (selenium, ferritin) are deficient, addressing them first may improve conversion capacity before any dose change. The plateau response should be determined by which mechanism is driving it, not by a default escalation approach.

Does the T3+T2 combination address the Wilson's plateau?

The T3+T2 enhanced protocol is the research-community response to the conversion-bottleneck presentation specifically. By pairing each T3 dose step with a matched T2 dose at a 1:1 mcg ratio, the approach bypasses DIO1 entirely for the T2 supply: 3,5-T2 is delivered directly to mitochondrial cytochrome c oxidase without requiring conversion from T3. This makes the mitochondrial activation pathway independent of DIO1 function. The Wilson's T3+T2 Combo is the reference formulation for this approach. The combination does not address the rT3 re-accumulation pattern or the cofactor-deficiency pattern, which require different interventions.

Can selenium deficiency cause Wilson's protocol plateau?

Yes. DIO1 is a selenoprotein - its catalytic function depends on selenocysteine at the active site, which requires adequate selenium for synthesis. Selenium deficiency reduces DIO1 activity, impairing both the T4-to-T3 conversion step and the T3-to-T2 downstream conversion step simultaneously. A research subject running the Wilson's protocol with selenium deficiency has impaired conversion capacity at the foundational enzyme level. Selenium repletion before further T3 dose escalation is a standard step in the research-community plateau response, because restoring enzyme cofactor availability may partially restore conversion capacity without requiring higher T3 input or T2 supplementation.

What if my reverse T3 rises during Wilson's protocol?

Rising rT3 on labs during the sustained high-T3 phase of the Wilson's protocol is a signal of DIO3 compensatory upregulation - the enzyme is processing the high exogenous T3 input into rT3 as a protective response. The research-community response is to initiate the planned taper rather than pushing the T3 dose higher; escalating T3 in response to rising rT3 provides more substrate for the overactive DIO3 rather than correcting the enzyme imbalance. The taper allows T4 substrate and T3 input to fall, reducing the DIO3 stimulus. During the inter-cycle interval, addressing upstream rT3 drivers (cortisol, inflammation) creates a better environment for the next cycle to succeed. For the full rT3 mechanism review, see the reverse T3 complete guide.

How long should I wait before assuming Wilson's plateau?

The Wilson's WT3 protocol allows up to three to seven days between dose increases for temperature stabilization assessment. A plateau is not confirmed on a single dose step that did not produce further temperature rise - it requires two to three consecutive dose increases without meaningful temperature progress, or a confirmed regression from a previously held temperature target. The research community generally suggests at least two full dose increments without progress before investigating plateau causes. Individual variation in response timing is substantial; some research subjects show delayed responses after dose changes that would register as a plateau if assessed too early. Temperature trend analysis over five to seven day windows at each dose step is more reliable than single-day readings for plateau assessment.

Closing Note

The Wilson's T3 plateau is a recognized and discussed pattern in the bioenergetic research community, not an anomaly or a sign that the protocol framework is fundamentally flawed. It reflects the biological reality that thyroid hormone metabolism involves multiple sequential conversion steps through a single enzyme family, and that the same conditions driving the original need for T3 protocol can impair multiple steps in that cascade simultaneously.

The conversion-bottleneck pattern - where adequate T3 is present but downstream T2 production is insufficient for full mitochondrial activation - is the mechanistic basis for the T3+T2 enhanced protocol response. Rather than continuing to escalate a T3 dose that is already above what nuclear receptor signaling requires, the enhanced approach adds Wilson's T3+T2 Combo to bypass the DIO1 conversion step and deliver 3,5-T2 directly to cytochrome c oxidase. The full titration structure, monitoring protocol, and how the T2 component integrates with the cyclic Wilson's framework are detailed in the Wilson's T3+T2 Enhanced Protocol guide.

For researchers beginning to work through the plateau response and wanting a systematic framework for the full SR-T3 titration and troubleshooting sequence, the slow-release T3 dosing troubleshooting complete guide is the primary reference. The full range of thyroid research compounds is available in the catalog.